Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
BUSINESS
BMS Files Repotrectinib in Japan for ROS1-Positive NSCLC
Bristol Myers Squibb said on October 25 that it has filed a new drug application for its ROS1 inhibitor repotrectinib for the treatment of ROS1-positive non-small cell lung cancer (NSCLC) in Japan. The submission rides on the back of the…
To read the full story
Related Article
BUSINESS
- J&J Submits Information Disclosure Requests to Japan Govt over Off-Year Revision
March 26, 2025
- Eisai Eyes Up to 280 Billion Yen Sales for Leqembi in FY2027: CEO
March 26, 2025
- Kaken Snags Japan Rights to Alumis’ Dermatology Asset
March 26, 2025
- MEDRx/DWTI Make 4th Attempt to Seek US Nod for Lidocaine Patch
March 26, 2025
- FRONTEO’s AI Engine Can Help Unearth Drug Targets, Predict Odds of Success: CTO
March 25, 2025
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…